Literature DB >> 16156682

Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.

Arti Hurria1, Anju Hurria, Kelly Brogan, Katherine S Panageas, Carol Pearce, Larry Norton, Ann Jakubowski, Jane Howard, Clifford Hudis.   

Abstract

OBJECTIVE: A number of age-related physiological changes contribute to an increased risk of toxicity of cancer chemotherapy in the elderly. One of the most important of these changes is the progressive decline in renal function with aging. We sought to determine the association between calculated creatinine clearance (CL(CR)) and grade 3 or 4 toxicities during adjuvant chemotherapy in women > or =65 years of age with breast cancer. DESIGN AND METHODS: We identified 1405 patients > or =65 years of age who had been treated for primary invasive breast cancer at Memorial Sloan-Kettering Cancer Center between January 1998 and December 2000. Patients were included in this analysis if they had stage I-III breast cancer and had received adjuvant chemotherapy. Patients were excluded if they had a prior history of breast cancer or chemotherapy, or had no baseline creatinine value available for review.
RESULTS: The 126 patients who met our criteria had received either cyclophosphamide, methotrexate and fluorouracil (CMF) [n = 65, mean age 71, range 65-78] or an anthracycline-based regimen (n = 61, mean age 69, range 65-79). The majority of patients (97%) had a normal creatinine. CL(CR), as calculated by the Cockcroft-Gault and Jeliffe formulas, decreased with increasing age (increased age associated with decreased Cockcroft-Gault [p = 0.02]; increased age associated with decreased Jeliffe [p < 0.01]). In multivariate analysis, after controlling for age and co-morbidity, a CL(CR) <50 mL/min by the Cockcroft-Gault formula was associated with an increased risk of fever and neutropenia (odds ratio [OR] 3.60; 95% CI 1.00, 12.94; p = 0.05) and a CL(CR) <50 mL/min by the Jeliffe formula was associated with a trend towards an increased risk of fever and neutropenia (OR 3.30; 95% CI 0.91, 12.33; p = 0.07), grade 3 or 4 haematological toxicity (OR 2.43; 95% CI 0.90, 6.55; p = 0.08), and need for erythropoietin (OR 4.15; 95% CI 0.81, 2.99; p = 0.09). An increase in creatinine (as a continuous variable) was associated with a trend towards an increased risk of grade 3 or 4 haematological toxicity (OR 5.81; 95% CI 0.96, 35.33; p = 0.06).
CONCLUSIONS: In this cohort of older breast cancer patients, a decreased CL(CR) and increased creatinine was associated with an increased risk of fever and neutropenia or haematological toxicity. CL(CR) should be considered when determining chemotherapy dosage in the elderly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16156682     DOI: 10.2165/00002512-200522090-00007

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  20 in total

Review 1.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  L B Grochow; M Colvin
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

Review 4.  Pharmacology of antineoplastic agents in older cancer patients.

Authors:  Stuart M Lichtman; J Andrew Skirvin; Sunitha Vemulapalli
Journal:  Crit Rev Oncol Hematol       Date:  2003-05       Impact factor: 6.312

5.  Patterns of breast cancer care in the elderly.

Authors:  E Busch; M Kemeny; A Fremgen; R T Osteen; D P Winchester; R E Clive
Journal:  Cancer       Date:  1996-07-01       Impact factor: 6.860

6.  Can creatinine clearance be accurately predicted by formulae in octogenarian in-patients?

Authors:  E Rimon; N Kagansky; L Cojocaru; J Gindin; A Schattner; S Levy
Journal:  QJM       Date:  2004-05

7.  Cancer treatment and age: patient perspectives.

Authors:  P A Newcomb; P P Carbone
Journal:  J Natl Cancer Inst       Date:  1993-10-06       Impact factor: 13.506

8.  Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance.

Authors:  R S Gelman; S G Taylor
Journal:  J Clin Oncol       Date:  1984-12       Impact factor: 44.544

9.  Factors associated with surgical and radiation therapy for early stage breast cancer in older women.

Authors:  R Ballard-Barbash; A L Potosky; L C Harlan; S G Nayfield; L G Kessler
Journal:  J Natl Cancer Inst       Date:  1996-06-05       Impact factor: 13.506

10.  Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.

Authors:  Xianglin L Du; Charles R Key; Cynthia Osborne; Jonathan D Mahnken; James S Goodwin
Journal:  Ann Intern Med       Date:  2003-01-21       Impact factor: 25.391

View more
  12 in total

1.  Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy.

Authors:  Abolfazl Razzaghdoust; Bahram Mofid; Maryam Moghadam
Journal:  Support Care Cancer       Date:  2018-05-07       Impact factor: 3.603

2.  Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors.

Authors:  Ajeet Gajra; Heidi D Klepin; Tao Feng; William P Tew; Supriya G Mohile; Cynthia Owusu; Cary P Gross; Stuart M Lichtman; Tanya M Wildes; Andrew E Chapman; Efrat Dotan; Vani Katheria; Laura Zavala; Chie Akiba; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2015-02-07       Impact factor: 3.599

Review 3.  [What is practically important when carrying out a chemotherapy?].

Authors:  M Schenck; T Jäger
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

4.  Age-dependent decline in renal function in patients with lung cancer.

Authors:  Gen Ohara; Koichi Kurishima; Kensuke Nakazawa; Mio Kawaguchi; Katsunori Kagohashi; Hiroichi Ishikawa; Nobuyuki Hizawa; Hiroaki Satoh
Journal:  Oncol Lett       Date:  2012-04-05       Impact factor: 2.967

5.  Association of Technetium(99m) MAG-3 renal scintigraphy with change in creatinine clearance following chemoradiation to the abdomen in patients with gastrointestinal malignancies.

Authors:  Kilian Salerno May; Gary Y Yang; Nikhil I Khushalani; Rameela Chandrasekhar; Gregory E Wilding; Leayn Flaherty; Harish K Malhotra; Richard C Russo; John C Warner; Johnny C Yap; Renuka V Iyer; Chukwumere E Nwogu; Saikrishna S Yendamuri; John F Gibbs; Hector R Nava; Dominick Lamonica; Charles R Thomas
Journal:  J Gastrointest Oncol       Date:  2010-09

6.  Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.

Authors:  Nan Jiang; Xiao-Cen Chen; Yue Zhao
Journal:  Support Care Cancer       Date:  2012-08-31       Impact factor: 3.603

Review 7.  Adjuvant chemotherapy for early breast cancer in the elderly.

Authors:  Mary Leung; Iulianna Shapira; Thomas Bradley; Daniel R Budman
Journal:  Curr Treat Options Oncol       Date:  2009-04-10

8.  Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.

Authors:  Mihaela A Popa; Kristie J Wallace; Antonella Brunello; Martine Extermann; Lodovico Balducci
Journal:  J Geriatr Oncol       Date:  2014-05-10       Impact factor: 3.599

9.  Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study.

Authors:  Jaime Feliu; Beatriz Jiménez-Munárriz; Laura Basterretxea; Irene Paredero; Elisenda Llabrés; Maite Antonio-Rebollo; Beatriz Losada; Enrique Espinosa; Regina Gironés; Ana Belén Custodio; María Del Mar Muñoz; Mariana Díaz-Almirón; Jeniffer Gómez-Mediavilla; Alvaro Pinto; María-Dolores Torregrosa; Gema Soler; Patricia Cruz; Oliver Higuera; María José Molina-Garrido
Journal:  Oncologist       Date:  2020-04-30       Impact factor: 5.837

10.  Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.

Authors:  Annelot G J van Rossum; Marleen Kok; Danielle McCool; Mark Opdam; Nienke C Miltenburg; Ingrid A M Mandjes; Elise van Leeuwen-Stok; Alex L T Imholz; Johanneke E A Portielje; Monique M E M Bos; Aart van Bochove; Erik van Werkhoven; Marjanka K Schmidt; Hendrika M Oosterkamp; Sabine C Linn
Journal:  Oncotarget       Date:  2017-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.